Satellos Bioscience Inc.
MSCL
Rang in Aktien
#17768
Satellos Bioscience Inc., a biotechnology firm established in 2018 and... Satellos Bioscience Inc., a biotechnology firm established in 2018 and headquartered in Toronto, Canada, specializes in developing regenerative therapies for degenerative muscle diseases. The company primarily operates in Canada and Australia, utilizing its proprietary MyoReGenX platform – an automated microscopy system engineered to replicate the muscle stem cell environment outside the body. A key focus for Satellos is the discovery and development of a small molecule drug specifically aimed at treating Duchenne muscular dystrophy.
Aktienkurs
$10.22
Zuletzt synchronisiert: 2026-07-31
Marktkapitalisierung
$212.97M
Veränderung (1 Tag)
4.58%
Veränderung (1 Jahr)
2,278.10%
Land
CA
Handel Satellos Bioscience Inc. (MSCL)
Kategorie
Healthcare
Kursverlauf für Satellos Bioscience Inc. (MSCL)
Höchster Schlusskurs: $0.48 am 2024-03-01
Niedrigster Schlusskurs: $12.71 am 2008-01-01
Niedrigster Schlusskurs: $12.71 am 2008-01-01
Kursverlauf der Aktie von Satellos Bioscience Inc. von 2008 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2024 | 43.42% |
| 2023 | 91.27% |
| 2022 | -80.10% |
| 2021 | 2.79% |
| 2020 | -11.41% |
| 2019 | 10.94% |
| 2018 | 37.66% |
| 2017 | -27.41% |
| 2016 | 41.02% |
| 2015 | -8.55% |
| 2014 | -90.26% |
| 2013 | -52.35% |
| 2012 | 195.82% |
| 2011 | -36.68% |
| 2010 | -30.40% |
| 2009 | 333.63% |
| 2008 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
